The CellSearchTM system (Veridex, LLC, Raritan, NJ, USA), depending on epithelial cell adhesion molecule (EpCAM) marker to enrich and isolate CTCs [18], was the first and only semi-automated CTCs enumeration assay approved by FDA for the diagnosis of metastatic breast, prostate, and colorectal cancers. This evidence concerns the gene EPCAM and colorectal cancer.